Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the role of macrophage-secreted UII in atherosclerosis progression, and evaluated the therapeutic value of urantide, a potent competitive UII receptor antagonist, in atherosclerosis treatment.
|
31685976 |
2019 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis and several other cardiovascular diseases; however, its role in the pathogenesis of AVS remains to be determined.
|
31679703 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urotensin II (UII), a secreted vasoactive peptide hormone, belonging somatostatin superfamily, plays an essential role in atherosclerosis and glucose metabolism.
|
29804270 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that UII may participate in macrophage activation and suggest a potential new mechanism underlying atherosclerosis.
|
31360201 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urotensin II and its receptor are thought to be involved in various cardiovascular diseases such as heart failure, pulmonary hypertension and atherosclerosis.
|
28163023 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
UII inhibition has been considered as beneficial strategy for atherosclerosis and restenosis.
|
28173642 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In previous investigations, U-II receptor antagonists have been shown to protect atherosclerosis in cell and animal models.
|
28363746 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results elucidated for the first time that autocrine UII plays an important role in the development of atherosclerosis by increasing the accumulation of macrophage-derived foam cell.
|
26640798 |
2015 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Urotensin II (UII) and its receptor UT are upregulated in the pathological setting of various cardiovascular diseases including atherosclerosis.
|
19111831 |
2009 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, in addition to its primary vasoactive effect, these observations suggest a role of U-II and UT receptor in the initiation and/or progression of atherosclerosis.
|
17933432 |
2008 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings qualitatively and quantitatively demonstrate increased expression of U-II in atherosclerosis with a large degree of inflammatory cell involvement.
|
15306183 |
2004 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Our findings qualitatively and quantitatively demonstrate increased expression of U-II in atherosclerosis with a large degree of inflammatory cell involvement.
|
15306183 |
2004 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that urotensin-II is a locally released vasoactive mediator that may be an important regulator of blood flow particularly to the myocardium and may have a specific role in human atherosclerosis.
|
15476944 |
2004 |